Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis

Journal of Neuroimmunology

Volumn 251, Issue 1-2, 2012, Pages 103-106

  Tewarie, P ^a   Teunissen, C E ^a   Dijkstra, C D ^a   Heijnen, D A M ^a   Vogt, M ^a   Balk, L ^a   Vrenken, H ^a   Polman, C H ^a   Killestein, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti myelin antibody; Biomarker; MRI; Multiple sclerosis

Indexed keywords

MYELIN; PROTEIN ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; AGED; AUTOANTIBODIES; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; SEVERITY OF ILLNESS INDEX;

EID: 84865653908     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.07.002     Document Type: Article

References (19)

1. Avsar T., Korkmaz D., Tütüncü M., Demirci N.O., Saip S., Kamasak M., Siva A., Turanli E.T. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Mult. Scler. J. 2012, 18:1081-1091. (Electronic publication ahead of print).
2. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mavringer I., Dilit E., Deisenhammer F., Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 2003, 349:139-145.
3. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
4. Breij E.C., Heijnen P., van der Goes A., Teunissen C.E., Polman C.H., Dijkstra C.D. Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients. J. Neuroimmunol. 2006, 176:106-114.
5. Klawiter E., Piccio L., Lyons J., Mikesell R., O'Connor K.C., Cross A.H. Intrathecal anti-MOG antibody production is elevated in multiple sclerosis. Arch. Neurol. 2010, 67:1102-1108.
6. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., Polman C.H., Miller D.H., Montalban X., Barkhof F., Bauer L., Dahms S., Lindberg R., Kappos L., Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 2007, 356:371-378.
7. Kuhle J., Lindberg R.L., Regeniter A., Mehling M., Hoffmann F., Reindl M., Berger T., Radue E.W., Leppert D., Kappos L. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J. Neurol. 2007, 254:160-168.
8. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
9. Lim E.T., Berger T., Reindl M., Dalton C.M., Fernando K., Keir G., Thompson E.J., Miller D.H., Giovannoni G. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult. Scler. 2005, 11:492-494.
10. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
11. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 2001, 50:121-127.
12. Olsson T. Roles of anti-MOG antibodies in demyelinating diseases. Nat. Rev. Neurol. 2011, 7:248-249.
13. Quintana F.J., Farez M.F., Izquierdo G., Lucas M., Cohen I.R., Weiner H.L. Antigen microarrays identify CNS-produced auto-antibodies in RRMS. Neurology 2012, 78:532-539.
14. Reindl M., Khalil M., Berger T. Antibodies as biological markers for pathophysiological processes in MS. J. Neuroimmunol. 2006, 180:50-62.
15. Teunissen C.E., Koel-Simmelink M.J.A., Pham T.V., Knol J.C., Khalil M., Trentini A., Killestein J., Nielsen J., Vrenken H., Popescu V., Dijkstra C.D., Jimenez C.R. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult. Scler. 2011, 17:838-850.
16. Tomassini V., de Giglio L., Reindl M., Russo P., Pestalozza I., Pantano P., Berger T., Pozzilli C. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult. Scler. 2007, 13:1086-1094.
17. Vergelli M., Kalbus M., Rojo S.C., Hemmer B., Kalbacher H., Tranquill L., Beck H., McFarland H.F., De Mars R., Long E.O., Martin R. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. J. Neuroimmunol. 1997, 77:195-203.
18. Vogt M., Teunissen C., Lacobaeus E., Heijnen D.A., Breij E.C., Olsson T., Brundin L., Killestein J., Dijkstra C.D. Cerebrospinal fluid ant-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80:1110-1115.
19. Weber M.S., Hemmer B., Cepok S. The role of antibodies in multiple sclerosis. Biochim. Biophys. Acta 2011, 1812:239-245.